Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Review Article

Current Leads and Marketed Formulations for an Effective Treatment of Fungal Infections

Author(s): Trambak Basak and Amit K. Goyal*

Volume 23, Issue 8, 2023

Published on: 10 August, 2023

Article ID: e260723219097 Pages: 14

DOI: 10.2174/1871526523666230726114855

Price: $65

Abstract

Severe antifungal infections, especially opportunistic fungal infections, are increasing tremendously in immunocompromised patients. This is basically because more patients enduring neoplastic diseases lead to the wide use of chemotherapy, thus causing immunosuppression. Patients with HIV infection, burns, pancreatitis and neutropenia are also amenable to fungal infections. Out of a plethora of antifungal drugs applied, Amphotericin B, being a broad-spectrum antimicrobial drug, has been the gold standard treatment for a diverse variety of fungal infections since the 1950s and visceral leishmaniasis since the 1960s. However, Amphotericin B has major constraints of poor bioavailability and kidney toxicity, due to which newer antifungal compounds are being used. This article discusses fungal and parasitic diseases and formulations for treating these ailments.

Keywords: Fungal infections, amphotericin B, non-parenteral formulations, self-emulsifying drug delivery systems, opportunistic fungal infections, kidney toxicity.

Graphical Abstract
[1]
Risovic V, Boyd M, Choo E, Wasan KM. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats. Antimicrob Agents Chemother 2003; 47(10): 3339-42.
[http://dx.doi.org/10.1128/AAC.47.10.3339-3342.2003] [PMID: 14506053]
[2]
Wasan KM, Wasan EK, Gershkovich P, et al. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis 2009; 200(3): 357-60.
[http://dx.doi.org/10.1086/600105] [PMID: 19545212]
[3]
Viscoli C, Castagnola E. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin b in the treatment of fungal infections in cancer patients: A review Int J Infect Dis 1999 1999; 3(2): 109-18.
[http://dx.doi.org/10.1016/S1201-9712(99)90019-X] [PMID: 10225990]
[4]
Hof H. A new, broad-spectrum azole antifungal: Posaconazole? mechanisms of action and resistance, spectrum of activity. Mycoses 2006; 49(s1 1): 2-6.
[http://dx.doi.org/10.1111/j.1439-0507.2006.01295.x] [PMID: 16961575]
[5]
Denning DW. Echinocandins: A new class of antifungal. J Antimicrob Chemother 2002; 49(6): 889-91.
[http://dx.doi.org/10.1093/jac/dkf045] [PMID: 12039879]
[6]
Garbino DJ. Aspergillosis. Orphanet Encyclopedia, August 2004. 2004.
[7]
Franquet T, Müller NL, Giménez A, Guembe P, de la Torre J, Bagué S. Spectrum of pulmonary aspergillosis: Histologic, clinical, and radiologic findings. Radiographics 2001; 21(4): 825-37.
[http://dx.doi.org/10.1148/radiographics.21.4.g01jl03825] [PMID: 11452056]
[8]
Pratap H, Dewan RK, Singh L, Gill S, Vaddadi S. Surgical treatment of pulmonary aspergilloma: A series of 72 cases. Indian J Chest Dis Allied Sci 2007; 49(1): 23-7.
[PMID: 17256563]
[9]
Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173(7): 707-17.
[http://dx.doi.org/10.1164/rccm.200505-727SO] [PMID: 16387806]
[10]
Barnes PD, Marr KA. Aspergillosis: Spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am 2006; 20(3): 545-61. [vi.
[http://dx.doi.org/10.1016/j.idc.2006.06.001] [PMID: 16984868]
[11]
Shakoor MT, Ayub S, Ayub Z, Mahmood F. fulminant invasive aspergillosis of the mediastinum in an immunocompetent host: A case report. J Med Case Reports 2012; 6(1): 311.
[http://dx.doi.org/10.1186/1752-1947-6-311] [PMID: 22989346]
[12]
Gupta N, Rajwanshi A. Pulmonary Infections. INTECH Open Access Publisher 2012.
[13]
Tsai YF, Ku YH. Necrotizing pneumonia. Curr Opin Pulm Med 2012; 18(3): 246-52.
[http://dx.doi.org/10.1097/MCP.0b013e3283521022] [PMID: 22388585]
[14]
Schop J. Protective immunity against cryptococcus neoformans infection. McGill J Med 2007; 10(1): 35-43.
[PMID: 18523595]
[15]
Baddley JW, Schain DC, Gupte AA, et al. Transmission of cryptococcus neoformans by organ transplantation. Clin Infect Dis 2011; 52(4): e94-8.
[http://dx.doi.org/10.1093/cid/ciq216] [PMID: 21220771]
[16]
Mesquita da Costa M, Martins Teixeira F, Ribeiro Schalcher T, Thielli Figueiredo Magalhães de Brito M, Silva Valerio E, Chagas Monteiro M. Cryptococcosis, a risk for immunocompromised and immunocompetent individuals. Open J Epidemiol 2013; 6(1)
[17]
Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2016; 30(1): 179-206.
[http://dx.doi.org/10.1016/j.idc.2015.10.006] [PMID: 26897067]
[18]
Curtis AC, Bocobo FC. North american blastomycosis. J Chronic Dis 1957; 5(4): 404-29.
[http://dx.doi.org/10.1016/0021-9681(57)90112-1] [PMID: 13416355]
[19]
Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46(12): 1801-12.
[http://dx.doi.org/10.1086/588300] [PMID: 18462107]
[20]
Grohskopf LA, Andriole VT. Systemic candida infections. Yale J Biol Med 1996; 69(6): 505-15.
[PMID: 9436294]
[21]
Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M. Treatment of invasive candidal infections: Systematic review and meta-analysis. Mayo Clin Proc 2008; 83: 1011-21.
[http://dx.doi.org/10.4065/83.9.1011]
[22]
Gallis HA, Drew RH, Pickard WW. Amln B: 30 Lience. Clin Infect Dis 1990; 12(2): 308-29.
[http://dx.doi.org/10.1093/clinids/12.2.308] [PMID: 2184499]
[23]
Jin KW, Jeon HS, Hyon JY, Wee WR, Suh W, Shin YJ. A case of fungal keratitis and onychomycosis simultaneously infected by trichophyton species. BMC Ophthalmol 2014; 14(1): 90.
[http://dx.doi.org/10.1186/1471-2415-14-90] [PMID: 25015110]
[24]
Insan NG, Mane V, Chaudhary B, Danu MS, Yadav A, Srivastava V. A review of fungal keratitis: Etiology and laboratory diagnosis. Int J Curr Microbiol Appl Sci 2013; 2(6): 307-14.
[25]
Mravičić I, Dekaris I, Gabrić N, Romac I, Glavota V, Mlinarić- Missoni E. An overview of fungal keratitis and case report on trichophyton keratitis. Keratitis 2012; pp. 1-14.
[26]
Harris JR, Balajee SA, Park BJ. pneumocystis jirovecii pneumonia: Current knowledge and outstanding public health issues. Curr Fungal Infect Rep 2010; 4(4): 229-37.
[http://dx.doi.org/10.1007/s12281-010-0029-3]
[27]
Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows pneumocystis carinii to be a member of the fungi. Nature 1988; 334(6182): 519-22.
[http://dx.doi.org/10.1038/334519a0] [PMID: 2970013]
[28]
Mori S, Cho I, Sugimoto M. A cluster of Pneumocystis jirovecii infection among outpatients with rheumatoid arthritis. J Rheumatol 2010; 37(7): 1547-8.
[http://dx.doi.org/10.3899/jrheum.091294] [PMID: 20595296]
[29]
Kwon-Chung KJ, Bennett JE. Medical mycology. Rev Inst Med Trop São Paulo 1992; 34(6): 504-4.
[http://dx.doi.org/10.1590/S0036-46651992000600018]
[30]
Davis BA. Sporotrichosis. Dermatol Clin 1996; 14(1): 69-76.
[http://dx.doi.org/10.1016/S0733-8635(05)70326-0] [PMID: 8821159]
[31]
Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Infectious Diseases Society of America. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the infectious diseases society of america. Clin Infect Dis 2007; 45(10): 1255-65.
[http://dx.doi.org/10.1086/522765] [PMID: 17968818]
[32]
Donabedian H, O’Donnell E, Olszewski C, MacArthur RD, Budd N. Disseminated cutaneous and meningeal sporotrichosis in an AIDS patient. Diagn Microbiol Infect Dis 1994; 18(2): 111-5.
[http://dx.doi.org/10.1016/0732-8893(94)90075-2] [PMID: 8062528]
[33]
Bolao F, Podzamczer D, Ventin M, Gudiol F. Efficacy of acute phase and maintenance therapy with itraconazole in an AIDS patient with sporotrichosis. Eur J Clin Microbiol Infect Dis 1994; 13(7): 609-12.
[http://dx.doi.org/10.1007/BF01971316] [PMID: 7805693]
[34]
Samson R, Yilmaz N, Houbraken J, et al. Phylogeny and nomenclature of the genus talaromyces and taxa accommodated in penicillium subgenus biverticillium. Stud Mycol 2007; 59(1): v-v.
[PMID: 22308048]
[35]
Le T, Kinh NV, Cuc NTK, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis. N Engl J Med 2017; 376(24): 2329-40.
[http://dx.doi.org/10.1056/NEJMoa1613306] [PMID: 28614691]
[36]
Vanittanakom N, Cooper CR Jr, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev 2006; 19(1): 95-110.
[http://dx.doi.org/10.1128/CMR.19.1.95-110.2006] [PMID: 16418525]
[37]
Jiang J, Meng S, Huang S, et al. Effects of talaromyces marneffei infection on mortality of hiv/aids patients in southern china: A retrospective cohort study. Clin Microbiol Infect 2019; 25(2): 233-41.
[http://dx.doi.org/10.1016/j.cmi.2018.04.018] [PMID: 29698815]
[38]
Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: Current epidemiological trends. Clin Infect Dis 2006; 43(1): S3-S14.
[http://dx.doi.org/10.1086/504490]
[39]
Greenberg RN, Mullane K, van Burik JAH, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50(1): 126-33.
[http://dx.doi.org/10.1128/AAC.50.1.126-133.2006] [PMID: 16377677]
[40]
Skiada A, Rigopoulos D, Larios G, Petrikkos G, Katsambas A. Global epidemiology of cutaneous zygomycosis. Clin Dermatol 2012; 30(6): 628-32.
[http://dx.doi.org/10.1016/j.clindermatol.2012.01.010] [PMID: 23068150]
[41]
Muma M, Chipalo-Mutati G. Deadly orbital mucormycosis, rare yet possible infection. Med J Zambia 2010; 37(4): 268-72.
[42]
Wahab NA, Mohd R, Zainudin S, Kamaruddin NA. Adrenal involvement in histoplasmosis. EXCLI J 2013; 12: 1-4.
[PMID: 27047312]
[43]
Avirup Guha M. Histoplasmosis Fungal Infection. In Patient Information Series. American Thorasic Society. 2012; 185: pp. 1-2.
[44]
Anstead GM, Graybill JR. Coccidioidomycosis. Infect Dis Clin North Am 2006; 20(3): 621-43.
[http://dx.doi.org/10.1016/j.idc.2006.06.005] [PMID: 16984872]
[45]
Coccidioidomycosis Fahy A. Am J Respir Crit Care Med 2011; 18: 2.
[46]
Ghannoum MA, Rice LB. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12(4): 501-17.
[http://dx.doi.org/10.1128/CMR.12.4.501] [PMID: 10515900]
[47]
Stoltz JH, Johnson BJ, Walker RL, Pappagianis D. Coccidioides immitis abortion in an Arabian mare. Vet Pathol 1994; 31(2): 258-9.
[http://dx.doi.org/10.1177/030098589403100217] [PMID: 8203093]
[48]
Sutton DA. Diagnosis of coccidioidomycosis by culture: Safety considerations, traditional methods, and susceptibility testing. Ann N Y Acad Sci 2007; 1111(1): 315-25.
[http://dx.doi.org/10.1196/annals.1406.005] [PMID: 17363439]
[49]
Bhat S, Shivakumar HG. Bioadhesive controlled release clotrimazole vaginal tablets. Trop J Pharm Res 2010; 9(4)
[http://dx.doi.org/10.4314/tjpr.v9i4.58924]
[50]
Llabot JM, Manzo RH, Allemandi DA. Double-layered mucoadhesive tablets containing nystatin. AAPS PharmSciTech 2002; 3(3)E22
[PMID: 12916937]
[51]
Dhake A, Shinkar DM, Shayle S, Patil SB, Setty CM. Development and evaluation of mucoadhesive tablets of clotrimazole and its β-cyclodextrin complex for the treatment of Candidiasis. Int J Pharm Pharm Sci 2011; 3(3): 159-64.
[52]
Zhang P, Yang X, He Y, et al. Preparation, characterization and toxicity evaluation of amphotericin B loaded MPEG-PCL micelles and its application for buccal tablets. Appl Microbiol Biotechnol 2017; 101(19): 7357-70.
[http://dx.doi.org/10.1007/s00253-017-8463-6] [PMID: 28868587]
[53]
Lenczuk D, Zinke-Cerwenka W, Greinix H, et al. Antifungal prophylaxis with posaconazole delayed-release tablet and oral suspension in a real-life setting: Plasma levels, efficacy, and tolerability. Antimicrob Agents Chemother 2018; 62(6): e02655-17.
[http://dx.doi.org/10.1128/AAC.02655-17] [PMID: 29581116]
[54]
You L, Qian W, Yang Q, et al. ERG11 gene mutations and MDR1 upregulation confer pan-azole resistance in Candida tropicalis causing disseminated candidiasis in an acute lymphoblastic leukemia patient on posaconazole prophylaxis. Antimicrob Agents Chemother 2017; 61(7): e02496-16.
[http://dx.doi.org/10.1128/AAC.02496-16] [PMID: 28507109]
[55]
Kapsi SG, Ayres JW. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int J Pharm 2001; 229(1-2): 193-203.
[http://dx.doi.org/10.1016/S0378-5173(01)00867-5] [PMID: 11604272]
[56]
RUBIN A. W. M. Tetracycline and amphotericin B cream for mixed vaginal infections. S Afr Med J 1983; 63: 3.
[57]
Rajalakshmi G, Damodharan N, Chaudhari V, Pogal J. Formulation and evaluation of clotrimazole and ichthammol ointment. Int J Pharma Bio Sci 2009; 4: 10-2.
[58]
Thomas L, Viswanad V. Formulation and optimization of clotrimazole-loaded proniosomal gel using 3(2) factorial design. Sci Pharm 2012; 80(3): 713-48.
[http://dx.doi.org/10.3797/scipharm.1201-03] [PMID: 23008818]
[59]
Bachhav Y, Patravale V. Microemulsion based vaginal gel of fluconazole: Formulation, In vitro and In vivo evaluation. Int J Pharm 2009; 365(1-2): 175-9.
[http://dx.doi.org/10.1016/j.ijpharm.2008.08.021] [PMID: 18790032]
[60]
Nawaz A, Jan SU, Khan NR, Hussain A, Khan GM. Formulation and In vitro evaluation of clotrimazole gel containing almond oil and tween 80 as penetration enhancer for topical application. Pak J Pharm Sci 2013; 26(3): 617-22.
[PMID: 23625439]
[61]
Kahn MA, Reddy IK. pharmaceutical and clinical calculations. Routledge 2000.
[62]
Noordin MI, Yong CL, Mofat I, Zainuddin Z, Arya A, Nyamathulla S. Evaluation of palm oil-based paracetamol suppositories by differential scanning calorimetry. Trop J Pharm Res 2014; 13(1): 23-9.
[http://dx.doi.org/10.4314/tjpr.v13i1.4]
[63]
Phillips AJ. Treatment of non-albicans candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol 2005; 192(6): 2009-12.
[http://dx.doi.org/10.1016/j.ajog.2005.03.034] [PMID: 15970877]
[64]
Kim YT, Shin BK, Garripelli VK, et al. A thermosensitive vaginal gel formulation with HPγCD for the pH-dependent release and solubilization of amphotericin B. Eur J Pharm Sci 2010; 41(2): 399-406.
[http://dx.doi.org/10.1016/j.ejps.2010.07.009] [PMID: 20654712]
[65]
Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care 2008; 53(6): 699-723.
[PMID: 18501026]
[66]
Siraj Shaikh SN. Tarique Khan, Afsar Shaikh, et al. RECENT ADVANCES IN PULMONARY DRUG DELIVERY SYSTEM: A REVIEW Int J Appl Pharm 2010; 2(4): 5.
[67]
Diot P, Rivoire B, Le Pape A, et al. Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J 1995; 8(8): 1263-8.
[http://dx.doi.org/10.1183/09031936.95.08081263] [PMID: 7489788]
[68]
Zu Y, Sun W, Zhao X, et al. Preparation and characterization of amorphous amphotericin B nanoparticles for oral administration through liquid antisolvent precipitation. Eur J Pharm Sci 2014; 53: 109-17.
[http://dx.doi.org/10.1016/j.ejps.2013.12.005] [PMID: 24345795]
[69]
Sangeetha S, Venkatesh DN, Adhiyaman R, Santhi K, Suresh B. Formulation of sodium alginate nanospheres containing amphotericin B for the treatment of systemic candidiasis. Trop J Pharm Res 2007; 6(1): 653-9.
[http://dx.doi.org/10.4314/tjpr.v6i1.14643]
[70]
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci 2009; 71(4): 349-58.
[http://dx.doi.org/10.4103/0250-474X.57282] [PMID: 20502539]
[71]
Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release 2006; 114(1): 53-9.
[http://dx.doi.org/10.1016/j.jconrel.2006.05.010] [PMID: 16828192]
[72]
Patel PA, Patravale VB. Ambionp: Solid lipid nanoparticles of amphotericin B for oral administration. J Biomed Nanotechnol 2011; 7(5): 632-9.
[http://dx.doi.org/10.1166/jbn.2011.1332] [PMID: 22195480]
[73]
Samein LH. Preparation and evaluation of nystatin loaded-solid-lipid nanoparticles for topical delivery. Int J Pharm Pharm Sci 2014; 6(2): 592-7.
[74]
Sachan R, Khatri K, Kasture S. Self-emulsifying drug delivery system a novel approach for enhancement of bioavailability. Int J Pharm Tech Res 2010; 2(3): 1738-45.
[75]
Tang J, Sun J, Cui F, He Z. Preparation of self-emulsifying drug delivery systems of ginkgo biloba extracts and in vitro dissolution studies Asian traditional medicine 2006; 1(3-4): 138-41.
[76]
Hong JY, Kim JK, Song YK, Park JS, Kim CK. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release 2006; 110(2): 332-8.
[http://dx.doi.org/10.1016/j.jconrel.2005.10.002] [PMID: 16297483]
[77]
Gershkovich P, Sivak O, Wasan EK, et al. Biodistribution and tissue toxicity of amphotericin b in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009). J Antimicrob Chemother 2010; 65(12): 2610-3.
[http://dx.doi.org/10.1093/jac/dkq358] [PMID: 20861140]
[78]
Sachs-Barrable K, Lee SD, Wasan EK, Thornton SJ, Wasan KM. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin b formulation for the treatment of systemic fungal infections. Adv Drug Deliv Rev 2008; 60(6): 692-701.
[http://dx.doi.org/10.1016/j.addr.2007.08.042] [PMID: 18053611]
[79]
Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000; 45(1): 89-121.
[http://dx.doi.org/10.1016/S0169-409X(00)00103-4] [PMID: 11104900]
[80]
Muzaffar F, Singh U, Chauhan L. Review on microemulsion as futuristic drug delivery. Int J Pharm Pharm Sci 2013; 5(3): 39-53.
[81]
Silva AE, Barratt G, Chéron M, Egito EST. Development of oil-in-water microemulsions for the oral delivery of amphotericin B. Int J Pharm 2013; 454(2): 641-8.
[http://dx.doi.org/10.1016/j.ijpharm.2013.05.044] [PMID: 23726904]
[82]
Gonjari ID, Hosmani AH, Karmarkar AB, Godage AS, Kadam SB, Dhabale PN. Formulation and evaluation of in situ gelling thermoreversible mucoadhesive gel of fluconazole. Drug Discov Ther 2009; 3(1): 6-9.
[PMID: 22495461]
[83]
Mitkari B, Korde S, Mahadik K, Kokare C. Formulation and evaluation of topical liposomal gel for fluconazole. Indian J Pharm Educ Res 2010; 44(4): 324-33.
[84]
Devi M, Kumar MS, Mahadevan N. Amphotericin-b loaded vesicular systems for the treatment of topical fungal infection. Int J Rec Adv Pharm Res 2011; 4: 37-46.
[85]
Layegh P, Rajabi O, Jafari M R, et al. Efficacy of topical liposomal amphotericin b versus intralesional meglumine antimoniate (glucantime) in the treatment of cutaneous leishmaniasis. J Parasitol Res 2011; 2011
[86]
Tejada G, Piccirilli GN, Sortino M, Salomón CJ, Lamas MC, Leonardi D. Formulation and in-vitro efficacy of antifungal mucoadhesive polymeric matrices for the delivery of miconazole nitrate. Mater Sci Eng C 2017; 79: 140-50.
[http://dx.doi.org/10.1016/j.msec.2017.05.034] [PMID: 28629000]
[87]
Liu M, Chen M, Yang Z. design of amphotericin b oral formulation for antifungal therapy. Drug Deliv 2017; 24(1): 1-9.
[http://dx.doi.org/10.1080/10717544.2016.1225852] [PMID: 28155335]
[88]
Mohamed HA, Radwan RR, Raafat AI, Ali AEH. Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: In vitro and In vivo study. Drug Deliv Transl Res 2018; 8(1): 191-203.
[http://dx.doi.org/10.1007/s13346-017-0452-x] [PMID: 29280061]
[89]
Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol 2013; 2(2): 47-64.
[http://dx.doi.org/10.5497/wjp.v2.i2.47] [PMID: 25590022]
[90]
Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010; 12(3): 348-60.
[http://dx.doi.org/10.1208/s12248-010-9183-3] [PMID: 20437123]
[91]
Serrano DR, Ruiz-Saldaña HK, Molero G, Ballesteros MP, Torrado JJ. A novel formulation of solubilised amphotericin b designed for ophthalmic use. Int J Pharm 2012; 437(1-2): 80-2.
[http://dx.doi.org/10.1016/j.ijpharm.2012.07.065] [PMID: 22890190]
[92]
Paul S, Mazumder R, Bhattacharya S, Jha A. An ex vivo study of amphotericin-B nanoparticle for ocular delivery. Br Biomed Bull 2013; 1(2): 119-25.
[93]
Ibrahim HM, Ismail HR, Lila AE. Formulation and optimization of ocular poly-d, l-lactic acid nano drug delivery system of amphotericin-b using box behnken design. Int J Pharm Pharm Sci 2012; 4(2): 342-9.
[94]
Zhou W, Wang Y, Jian J, Song S. Self-aggregated nanoparticles based on amphiphilic poly(lactic acid)-grafted-chitosan copolymer for ocular delivery of amphotericin B. Int J Nanomedicine 2013; 8: 3715-28.
[PMID: 24106427]
[95]
Vassilopoulos S, Mylonakis E. Avenues for antifungal drug discovery and development: Where to now? Expert Opin Drug Discov 2022; 17(7): 667-72.
[http://dx.doi.org/10.1080/17460441.2022.2098950] [PMID: 35790187]
[96]
Van Daele R, Spriet I, Wauters J, et al. Antifungal drugs: what brings the future?. Med Mycol 2019; 57(3 3): S328-43.
[http://dx.doi.org/10.1093/mmy/myz012] [PMID: 31292663]

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy
?>